Search results
Showing 1681 to 1695 of 2026 results for nice guidelines
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.
This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.
Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy (HTG167)
Evidence-based recommendations on intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. This involves collecting the solid components of the blood lost during an operation and transfusing it back to the same patient.
View recommendations for HTG167Show all sections
Sections for HTG167
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (HTG188)
Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).
View recommendations for HTG188Show all sections
Sections for HTG188
Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.
This medical technologies guidance has been replaced by the recommendation on cardiac output monitoring in the NICE guideline on perioperative care in adults.
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.
NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)
This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.
This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.
Interventional procedures, IPG51 - Issued: March 2004 --> This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding: assessment and management. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.